1. Lim KH, Counter CM. Leveling the playing field. Mol Cell. 2004 Aug27;15(4):491-2. PMID: 15327763
  1. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell. 2005 Jun;7(6):533-45. PMID: 15950903
  1. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell. 2005 Nov;8(5):381-92. PMID: 16286246
  1. Baines AT, Lim KH, Shields JM, Lambert JM, Counter CM, Der CJ, Cox AD. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol. 2006;407:556-74. PMID: 16757353
  1. Lim KH, O’Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol. 2006 Dec 19;16(24):2385-94. PMID: 17174914
  1. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007 Jul 15;21(14):1714-9. PMID: 17639077, PMCID: PMC1920165
  1. Lim KH*, Ancrile BB*, Kashatus DF*, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008 Apr 3;452(7187):646-9. doi: 10.1038/nature06778. Epub 2008 Mar. PMID: 18344980, PMCID: PMC2688829. (*co-first authors)
  1. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008 Sep 15;68(18):7561-9. doi:10.1158/0008-5472.CAN-08-0188. PMID: 18794144, PMCID:PMC2978070
  1. Lim KH, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, Counter CM. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol. 2010 Jan;30(2):508-23. doi: 10.1128/MCB.00916-08. Epub 2009 Nov 9. PMID: 19901077, PMCID: PMC2798468
  1. Issaq SH, Lim KH, Counter CM. Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis. Mol Cancer Res. 2010 Feb;8(2):223-31. doi:10.1158/1541-7786.MCR-09-0189. Epub 2010 Feb 9. PMID: 20145037, PMCID: PMC2824780
  1. Ngo VN*, Young RM*, Schmitz R*, Jhavar S*, Xiao W*, Lim KH*, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.PMID: 21179087, PMCID: PMC5024568 (*co-first authors)
  1. Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, Counter CM. RALA and RALBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol. 2011 Aug 7;13(9):1108-15. doi: 10.1038/ncb2310. PMID: 21822277, PMCID: PMC3167028
  1. Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17(2):192-200. doi: 10.1634/theoncologist.2011-0268. Epub 2012 Jan 16. PMID: 22250057, PMCID: PMC3286168
  1. Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev. 2012 Mar;246(1):359-78. doi: 10.1111/j.1600-065X.2012.01105.x. PMID: 22435566, PMCID: PMC4094296
  1. Lim KH, Staudt LM. Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 2013 Jan 1;5(1):a011247. doi: 10.1101/cshperspect.a011247. PMID: 23284045, PMCID: PMC3579400
  1. Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol. 2015 Mar;7(2):68-84. doi: 10.1177/1758834014564775. PMID:25755680, PMCID: PMC4346211
  1. Ur Rehman SS, Lim K, Wang-Gillam A. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert Rev Anticancer Ther. 2016 May;16(5):485-92. doi: 10.1080/14737140.2016.1174581. Epub 2016 Apr 22. PMID: 27043737
  1. Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4. PMID: 27055731, PMCID: PMC5407285
  1. Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Apr 1;23(7):1748-1759. doi: 10.1158/1078-0432.CCR-16-1121. Epub 2016 Oct 4. PMID: 27702822, PMCID: PMC5378683
  1. Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, Tan BR Jr, Wang-Gillam A, Morton AE, Ruzinova MB, Parikh PJ, Narra VR, Fowler KJ, Doyle MB, Chapman WC, Strasberg SS, Hawkins WG, Fields RC. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB (Oxford). 2017 Feb;19(2):133-139. doi: 10.1016/j.hpb.2016.11.002. Epub 2016 Dec 1. PMID: 27916436, PMCID: PMC5477647
  1. Lim KH, Langley E, Gao F, Luo J, Li L, Meyer G, Kim P, Singh S, Kushnir VM, Early DS, Mullady DK, Edmundowicz SA, Wani S, Murad FM, Cao D, Azar RR, Wang-Gillam A. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget. 2017 Apr 11;8(15):24250-24261. doi: 10.18632/oncotarget.15653. PMID: 28445954, PMCID: PMC5421844
  1. Grierson P, Lim KH, Amin M. Immunotherapy in gastrointestinal cancers. J Gastrointest Oncol. 2017 Jun;8(3):474-484. doi: 10.21037/jgo.2017.05.01. PMID: 28736635, PMCID: PMC5506270
  1. Zhao DY, Lim KH. Current biologics for treatment of biliary tract cancers. J Gastrointest Oncol. 2017 Jun;8(3):430-440. doi: 10.21037/jgo.2017.05.04. PMID: 28736630, PMCID: PMC5506280
  1. Fakhri B, Lim KH. Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. J Gastrointest Oncol. 2017 Jun;8(3):379-386. doi: 10.21037/jgo.2016.11.01. PMID: 28736626, PMCID: PMC5506283
  1. Wang-Gillam A, Lim KH. Entering the molecular era of gastrointestinal oncology: current updates and challenges. J Gastrointest Oncol. 2017 Jun;8(3):377-378. doi:10.21037/jgo.2017.05.02. PMID: 28736625, PMCID: PMC5506275
  1. Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, Dipersio JF, Kreisel FH, Lim KH. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Dec;23(12):2199-2204. doi: 10.1016/j.bbmt.2017.08.022. Epub 2017 Aug 26. PMID: 28847710
  1. Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC. Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. J Gastrointest Oncol. 2017 Dec;8(6):985-989. doi: 10.21037/jgo.2017.08.16. PMID: 29299358, PMCID: PMC5750170
  1. Grierson P, Crites D, Ruzinova MB, Yano M, and Lim KH. Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression. Hepatology Communications 2018, 2: 148–151. doi:10.1002/hep4.1132
  1. Zhang D, Li L, Jiang H, Li Q, Wang-Gillam A, Yu J, Head R, Liu J, Ruzinova MB, Lim KH. Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res. 2018 Jan 23. pii: canres.1366.2017. doi: 10.1158/0008-5472.CAN-17-1366. PMID: 29363544
  1. Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, Zhang D, Li Q, Wang-Gillam A, Lim KH. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Molecular cancer therapeutics. 2018;17(10):2144-55.
  1. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan BR, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura MI, Carmagnani Pestana R, Qiao W, Xiao L, Morris J, Amin HM, Hassam MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills Shaw KR, George B, Haque A, Raghav K, Wolf RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA. Clin Cancer Res. 2019 Jul 30;. doi: 10.1158/1078-0432.CCR-18-3341. [Epub ahead of print] PubMed PMID: 31363003.
  1. Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y. Folate Receptor alpha-Targeted (89)Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer. Mol Pharm. 2019;16(9):3996-4006.
  1. Li Q, Chen Y, Zhang D, Grossman J, Li L, Khurana N, Jiang H, Grierson PM, Herndon J, DeNardo DG, Challen GA, Liu J, Ruzinova MB, Fields RC, Lim KH. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. JCI Insight. 2019 Oct 3;4(19). pii: 130867. doi: 10.1172/jci.insight.130867. PMID: 31527315
  1. Cercek A, Boerner T, Tan BR, Chou JF, Gonen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D’Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA, Jr., Kemeny NE, Jarnagin WR. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2019.
  1. Grierson P, Teague A, Suresh R, Lim KH, Amin M, Pedersen K, Tan B, Huffman J, Boice N, Du L, Liu J, Lockhart AC, Wang-Gillam A. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2020 Feb;11(1):61-67. doi: 10.21037/jgo.2019.11.06. PubMed PMID: 32175106; PubMed Central PMCID: PMC7052765.
  1. Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jané-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe’er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell. 2020 Apr 16;181(2):236-249. doi: 10.1016/j.cell.2020.03.053. Review. PubMed PMID: 32302568.
  1. Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol2020 May 29;doi: 10.1001/jamaoncol.2020.2020. PubMed PMID: 32469386; PubMed Central PMCID: PMC7260693.
  1. Dang HX, Krasnick BA, White BS, Grossman JG, Strand MS, Zhang J, Cabanski CR, Miller CA, Fulton RS, Goedegebuure SP, Fronick CC, Griffith M, Larson DE, Goetz BD, Walker JR, Hawkins WG, Strasberg SM, Linehan DC, Lim KH, Lockhart AC, Mardis ER, Wilson RK, Ley TJ, Maher CA, Fields RC. The clonal evolution of metastatic colorectal cancer. Sci Adv. 2020;6(24):eaay9691.
  1. Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. J Clin Invest. 2020 Jun 23:137660. doi: 10.1172/JCI137660.
  1. Khurana N, Dodhiawala PB, Bulle A, Lim KH. Deciphering the Role of Innate Immune NF-kB Pathway in Pancreatic Cancer. Cancers (Basel). 2020;12(9).(1)
  1. Bulle A, Lim KH. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther. 2020;5(1):249.
Print Friendly, PDF & Email